Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​​Aduhelm™​​​ for treatment of Alzheimer’s disease considered experimental/investigational

July 8, 2021

​Aduhelm (aducanumab-avwa) injection is considered experimental/investigational for Independence commercial members and is not covered for treatment of Alzheimer's disease. 

We continue to monitor for the Centers for Medicare & Medicaid Services coverage position so that we can be sure our coverage policies for Medicare Advantage members align with their decisions.

We have evaluated the published peer-reviewed literature on the evidence of Aduhelm's safety and effectiveness in treating Alzheimer's disease. We have concluded that it does not sufficiently show that the drug's clinical benefits outweigh its harms or that it reduces progression of the disease.

Other uses for Aduhelm and services associated with Aduhelm, including but not limited to radiological examinations, are not covered. 

For more information about the coverage of Aduhelm, including background and coding, please read our News Articles on the Commercial and Medicare Advantage Medical and Claim Payment Policy Portals.​


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.